XERIS BIOPHARMA HOLDINGS, INC. (XERS)

Every figure this model derived for XERS, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 0 PaymentsToAcquirePropertyPlantAndEquipment 2021-12-31
cash 121,747,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 274,757,000 AssetsCurrent 2026-06-30
current liabilities 189,568,000 LiabilitiesCurrent 2026-06-30
equity -9,734,000 StockholdersEquity 2026-06-30
interest expense 28,252,000 InterestExpenseNonoperating 2026-06-30
ocf 56,608,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 335,414,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 28,121,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up XERS on one particular measure came for.

RatioValue
cash operating margin19.69
current ratio1.45
current ratio reported1.45
dilution pct17.71
fcf margin16.88
growth cv0.62
interest cover1.3
net debt ebitda5.13
operating margin10.91
owner earnings margin8.49
revenue growth36.33
revenue growth per share15.82
roic15.64
rule of 4047.24
sbc pct revenue8.38

What to be careful about

What this model itself distrusts about XERS's figures. Written by the derivation as it ran, not added afterwards.